ライフサイエンスコーパス: protein-tyrosine kinase

1 itors against C-terminal Src kinase (Csk), a protein tyrosine kinase.

2 which subsequently bind and activate the Syk protein tyrosine kinase.

3 neages, functions as a constitutively active protein-tyrosine kinase.

4 tor signalling that acts on receptor-coupled protein tyrosine kinases.

5 sis are regulated by the TGFbeta pathway and protein tyrosine kinases.

6 e hydrogen-bonding pattern seen in wild-type protein tyrosine kinases.

7 ny cardiomyocyte signaling pathways activate protein tyrosine kinases.

8 resent two general regulatory strategies for protein tyrosine kinases.

9 icity mechanisms for cancer agents targeting protein tyrosine kinases.

10 ation of these GEFs is fully mediated by JAK protein tyrosine kinases.

11 sion or activation of TGF-beta1 and receptor protein tyrosine kinases.

12 s of substrate specificity and regulation of protein tyrosine kinases.

13 adapter proteins that modulate signaling by protein tyrosine kinases.

14 bstrate recognition and specificity of other protein tyrosine kinases.

15 that initiates TCR signalling by recruiting protein tyrosine kinases.

16 essential tumor survival factors, primarily protein tyrosine kinases.

17 d in the regulation of signaling mediated by protein-tyrosine kinases.

18 is a member of the Src-family of nonreceptor protein-tyrosine kinases.

19 family of sperm-expressed non-receptor-like protein-tyrosine kinases.

20 ingly, miR-495 is positively associated with protein tyrosine kinase 2 (PTK2) in both groups.

21 REACH patients with higher pretreatment protein tyrosine kinase 2 (PTK2) messenger RNA levels de

22 Expression of one such gene, that encoding protein tyrosine kinase 2 (ptk2, also known as focal adh

23 Non-receptor tyrosine kinase proline-rich protein tyrosine kinase 2 (Pyk2) functions as an integra

24 Protein tyrosine kinase 2 (Pyk2) is required for T cell

25 functions of FAK are shared by its homolog, protein tyrosine kinase 2 (Pyk2), raising the question a

26 ncoupled the TLR4 cascade from activation of protein tyrosine kinase 2 (PYK2; also known as PTK2B).

27 nd the Alzheimer's disease risk gene product protein tyrosine kinase 2 beta.

28 The focal adhesion kinase (FAK) gene protein tyrosine kinase 2 is amplified in 16.4% of The C

29 enes, namely PKN2 (protein kinase N2), PTK2 (protein tyrosine kinase 2), and ALPP (alkaline phosphata

30 iggers the phosphorylation and activation of protein-tyrosine kinase 2-beta (PTK2B, also referred to

31 e activity, including focal adhesion kinase, protein tyrosine kinase-2, Janus kinase, other focal adh

32 , also known as cell adhesion kinase beta or protein tyrosine kinase 2b, is a calcium-dependent signa

33 Protein tyrosine kinase 6 (PTK6) (also called Brk or Sik

34 gulation, including the antiapoptotic factor protein tyrosine kinase 6 (PTK6) and the proapoptotic fa

35 Protein tyrosine kinase 6 (PTK6) is a non-receptor tyros

36 Protein tyrosine kinase 6 (PTK6) is a nonmyristoylated S

37 Here we report that protein tyrosine kinase 6 (PTK6) is expressed in approxi

38 Protein tyrosine kinase 6 (PTK6) is expressed in epithel

39 Protein tyrosine kinase 6 (PTK6) is expressed throughout

40 The intracellular tyrosine kinase protein tyrosine kinase 6 (PTK6) lacks a membrane-target

41 ified elevated expression of another kinase, protein tyrosine kinase 6 (PTK6), upon treatment with a

42 state cancer cell proliferation by targeting protein tyrosine kinase 6 (PTK6).

43 Protein tyrosine kinase 6 (PTK6, also called BRK) is an

44 Breast tumor kinase (Brk; protein tyrosine kinase 6) is a soluble tyrosine kinase

45 Protein-tyrosine kinase 6 (PTK6) is a non-myristoylated

46 We found that breast tumor kinase (Brk)/protein-tyrosine kinase 6 (PTK6), a nonreceptor protein-

47 with the progressive loss of markers such as protein tyrosine kinase 7 (PTK7) and platelet endothelia

48 We demonstrate that protein tyrosine kinase 7 (PTK7) is a novel marker for h

49 Protein tyrosine kinase 7 (PTK7) is a pseudokinase whose

50 Among WNT/PCP components, protein tyrosine kinase 7 (PTK7) is a tyrosine kinase re

51 Using an aptamer that binds to protein tyrosine kinase-7 (PTK7) that is overexpressed o

52 Protein tyrosine kinase-7 (PTK7), a member of receptor t

53 miR-106b, Bim of miR-32, and exportin-6 and protein tyrosine kinase 9 of miR-1.

54 The Syk protein tyrosine kinase, a well-characterized regulator

55 ated Ca(2+) response, required activation of protein tyrosine kinases, a functional TCR/CD3 complex,

56 The c-abl proto-oncogene encodes a unique protein-tyrosine kinase (Abl) distinct from c-Src, c-Fes

57 TYK2 is a JAK family protein tyrosine kinase activated in response to multipl

58 Protein tyrosine kinase activation due to phagocytosis m

59 evidence supporting the common mechanisms of protein tyrosine kinase activation in cancer and provide

60 nt and rapid way for producing several other protein tyrosine kinases, active Src is difficult to pro

61 ) and mitosis (BIRC5), and chemokine-related protein tyrosine kinase activity (CCL4).

62 on how effectively the drugs inhibit Bcr-Abl protein tyrosine kinase activity and inhibit tumor growt

63 ollagen formation and transmembrane receptor protein tyrosine kinase activity gene sets with the modu

64 and reusable label-free method for detecting protein tyrosine kinase activity using a tyrosinase-base

65 Inhibition of Src protein-tyrosine kinase activity or mutation of Src phos

66 finely tuned by the dynamic balance between protein tyrosine kinase and protein tyrosine phosphatase

67 provides new insights into the regulation of protein tyrosine kinases and establishes a potential con

68 The cooperative activity of protein tyrosine kinases and phosphatases plays a centra

69 tightly regulated by the opposing actions of protein tyrosine kinases and phosphatases, but little is

70 tion and mediated by the opposing actions of protein tyrosine kinases and phosphatases.

71 kinase was also blocked by inhibitors of Src protein tyrosine kinases and phospholipase PLCgamma, ups

72 reciprocal activation of receptor-associated protein tyrosine kinases and protein tyrosine phosphatas

73 e controlled by the balance of activation of protein tyrosine kinases and protein tyrosine phosphatas

74 cascade encompassing receptor-associated Jak protein tyrosine kinases and STAT (signal transducer and

75 This required the activation of Src protein-tyrosine kinase and p38-MAPK (and phosphoinositi

76 tional proteins reflects the balance between protein-tyrosine kinase and protein-tyrosine phosphatase

77 ngement-Rho kinase-integrin system, and both protein-tyrosine kinase and serine/threonine kinase rece

78 Non-receptor-tyrosine kinases (protein-tyrosine kinases) and non-receptor tyrosine phos

79 This activity requires a functional TrkC protein tyrosine kinase, and the BMPRII seems to be a di

80 rc and Fyn of the Src-family of non-receptor protein tyrosine kinases, and CrkL) are located adjacent

81 Protein tyrosine kinases are a family of signaling molec

82 Protein tyrosine kinases are attractive drug targets bec

83 Protein tyrosine kinases are critical cell signaling enz

84 Csk and Src protein tyrosine kinases are structurally homologous but

85 This indicates that altered protein tyrosine kinases are the main drivers of many di

86 s in mice and humans have implicated the Lyn protein tyrosine kinase as a regulator of Ab-mediated au

87 in the cytoplasm is in activation of the LCK protein tyrosine kinase at the outset of TCR signal tran

88 t in part by promoting activation of the LCK protein tyrosine kinase at the outset of the TCR signali

89 ion of a haemopoietic stem cell (HSC) by the protein-tyrosine kinase BCR-ABL.

90 through coupling to the adaptor protein TYRO protein-tyrosine kinase-binding protein (TYROBP).

91 e we describe constitutive expression of the protein tyrosine kinase Brk in a large proportion of cut

92 nnexin/connexin-conductive pathway involving protein tyrosine kinase, but independent from vesicular

93 le cell lineages, and functions as an active protein tyrosine kinase by neurotrophin-3 (NT-3).

94 esigning metal-mediated inhibitors against a protein tyrosine kinase by targeting a metal binding sit

95 The nonreceptor protein tyrosine kinase c-Abl regulates cell proliferati

96 annels (VDCCs) and require activation of the protein tyrosine kinase c-Src.

97 The nonreceptor protein-tyrosine kinase c-Src is frequently overexpresse

98 proto-oncogene encodes a unique nonreceptor protein-tyrosine kinase (c-Fes) that contributes to the

99 The catalytic domain of protein tyrosine kinases can interconvert between active

100 The Syk protein-tyrosine kinase can have multiple effects on can

101 ta, as in the reports of lymphocyte-specific protein tyrosine kinase, CD27, and CD21 deficiencies.

102 Protein-tyrosine phosphatases (PTPs) and protein-tyrosine kinases co-regulate cellular processes.

103 We show that Janus kinase (JAK) protein tyrosine kinases control chemokine-induced LFA-1

104 To determine whether Src-family protein tyrosine kinases could be responsible for the ob

105 Cas coimmunoprecipitates with Src family protein tyrosine kinases, Crk, and cell adhesion molecul

106 s with the panel of all publically available protein tyrosine kinases crystal structures.

107 r protein PAG1, which recruits the cytosolic protein tyrosine kinase Csk to the plasma membrane, wher

108 Prior studies on protein tyrosine kinases Csk and Src revealed the potent

109 ressor phosphatase PTEN, and the cytoplasmic protein-tyrosine kinase cSrc-p60), in the retina of the

110 Protein tyrosine kinases differ widely in their propensi

111 Focal adhesion kinase (FAK), a nonreceptor protein tyrosine kinase, displays phosphorylation-depend

112 F(V)2E dimerization domain and the cytosolic protein tyrosine kinase domain of the insulin receptor w

113 transcription factor to the C-terminal PTK (protein-tyrosine kinase) domain of the neurotrophin-3 re

114 EGFR extracellular domains and intracellular protein tyrosine kinase domains have suggested mechanism

115 ical inhibitors of Janus kinase (JAK) family protein tyrosine kinases, downstream effectors of the IF

116 ported that epidermal growth factor receptor protein tyrosine kinase (EGFR-PTK) signaling negatively

117 nhibitor of epidermal growth factor receptor-protein-tyrosine kinase (EGFR-PTK), which also restored

118 v-Abl protein tyrosine kinase encoded by Abelson murine leukem

119 ered a coincidence between activation of the protein-tyrosine kinase encoded by MET and activating mu

120 , blocking of both langerin and the receptor protein tyrosine kinase ephrin A2 was required to inhibi

121 The protein tyrosine kinase Ephrin type-B receptor 3 (EPHB3)

122 2 inducible T cell kinase) is a non-receptor protein tyrosine kinase expressed primarily in T cells.

123 nduced the association and activation of the protein-tyrosine kinases FAK1/PYK1 that phosphorylated L

124 Tyk2 belongs to the Janus protein tyrosine kinase family and is involved in signal

125 The overexpression of the protein tyrosine kinase, Focal adhesion kinase (FAK), in

126 eny, and function of the various prokaryotic protein-tyrosine kinases, focusing on the recently disco

127 Tnk1/Kos1 is a non-receptor protein tyrosine kinase found to be a tumor suppressor.

128 omb group ring finger 5 (PCGF5) protein, Src protein tyrosine kinase FYN (FYN), protein tyrosine phos

129 early independent of its ability to bind the protein tyrosine kinase Fyn and correlated with the capa

130 ion by coupling SLAM family receptors to the protein tyrosine kinase Fyn and the exchange factor Vav,

131 e and human IFITM3 are phosphorylated by the protein-tyrosine kinase FYN on tyrosine 20 (Tyr(20)) and

132 Remarkably, the protein-tyrosine kinase Fyn, which binds to the proline-

133 ast carcinoma cells to the inhibition of Syk protein tyrosine kinase giving insight into the signalin

134 performed using a membrane-tagged lymphocyte protein tyrosine kinase-green fluorescent protein (Lck-G

135 ed to occur extensively in vivo, no secreted protein tyrosine kinase has been identified.

136 The Src protein tyrosine kinase has been implicated in many of t

137 tein-tyrosine kinase 6 (PTK6), a nonreceptor protein-tyrosine kinase highly expressed in most human b

138 Tnk1/Kos1 is a non-receptor protein tyrosine kinase implicated in negatively regulat

139 The human c-fes locus encodes a non-receptor protein-tyrosine kinase implicated in myeloid, vascular

140 heat shock protein 90 to lymphocyte-specific protein tyrosine kinase in vitro, disrupting lymphocyte-

141 While the importance of protein tyrosine kinases in orchestrating the tyrosine p

142 belonging to the superfamily of prokaryotic protein-tyrosine kinases in bacteria.

143 relevance of Nef interactions with host cell protein-tyrosine kinases in the broader context of Nef f

144 e Src family kinase Lck (lymphocyte-specific protein tyrosine kinase) in critical membrane-proximal p

145 Src homology 2 (SH2) domain to a variety of protein tyrosine kinases, including JAK2 and the insulin

146 B is recruited via its SH2 domain to various protein tyrosine kinases, including Janus kinase-2 (Jak2

147 Experiments on two additional protein tyrosine kinases indicate that the allosteric ne

148 strin Homology (PH) domain of the Tec family protein tyrosine kinase, Inducible T cell Kinase (ITK),

149 tyrosine phosphorylation, we have designed a protein tyrosine kinase-inducible domain, a small, genet

150 Genistein, a broad-range protein tyrosine kinase inhibitor, inhibited the phospho

151 d in cultured microglia by PP2, a Src family protein tyrosine kinase inhibitor.

152 Furthermore, genistein, a protein-tyrosine kinase inhibitor, impeded T-Cad degrada

153 In addition, intracellular application of protein tyrosine kinase inhibitors (lavendustin A or PP2

154 duplication), confers resistance to the FLT3 protein tyrosine kinase inhibitors (PTKIs) PKC412 and AC

155 The introduction of protein tyrosine kinase inhibitors (TKIs) in 1998 transf

156 ibitors that block neuregulin cleavage, erbB protein tyrosine kinase inhibitors, or antineuregulin-ne

157 Multiple clinically relevant RET protein-tyrosine kinase inhibitors (TKIs) have been iden

158 ndothelial cells with specific inhibitors of protein tyrosine kinases inhibits KSHV-induced Ca(2+) in

159 en tyrosine kinase (SYK) is an intracellular protein tyrosine kinase involved in cell signaling downs

160 esion kinase (FAK), an important nonreceptor protein tyrosine kinase involved in integrin signaling,

161 Inhibitors of more upstream protein-tyrosine kinases involved in cellular signaling

162 esylate and PD-173955 kinase inhibitors with protein tyrosine kinases is conducted on kinome scale by

163 The Syk protein-tyrosine kinase is an essential component of the

164 The Syk protein-tyrosine kinase is phosphorylated on multiple ty

165 tor receptor (also known as Met), a receptor protein tyrosine kinase, is a major regulator of prolife

166 The gene encoding c-ABL, a nonreceptor protein tyrosine kinase, is involved in a chromosomal tr

167 , focal adhesion kinase (FAK), a nonreceptor protein tyrosine kinase, is shown to structurally intera

168 this was required for full activation of the protein tyrosine kinase Itk after T cell receptor engage

169 g associated with strong lymphocyte-specific protein tyrosine kinase/JAK3-dependent activation of the

170 ated through the inhibition of activation of protein tyrosine kinases Janus-activated kinase 2 and c-

171 ol 3-kinase, Bruton tyrosine kinase, and the protein tyrosine kinase KIT).

172 ive for FLT3 relative to the closely related protein tyrosine kinase KIT, demonstrating that simultan

173 stroma through the release of the oncogenic protein tyrosine kinase (KIT)-containing exosomes, which

174 s with and activates the oncogene Fes/Fps, a protein-tyrosine kinase known to be involved in myeloid

175 line motif that promotes lymphocyte-specific protein tyrosine kinase Lck binding to the CD28 cytosoli

176 subcellular localization and function of the protein tyrosine kinase Lck depends on the Rab11 effecto

177 The protein tyrosine kinase LCK plays a key role in TCR sign

178 Thymic selection requires signaling by the protein tyrosine kinase Lck to generate T cells expressi

179 In this study, we show that the protein tyrosine kinase Lck, the TCRzeta subunit, and th

180 switch in the expression of the Src-related protein tyrosine kinases Lck and Lyn.

181 LFA-1 is constitutively associated with the protein tyrosine kinases Lck and zeta chain-associated p

182 rylation is dependent on lymphocyte-specific protein tyrosine kinase (Lck) activity, which in turn is

183 cells (TEM) that >50% of lymphocyte-specific protein tyrosine kinase (Lck) exists in a constitutively

184 asma membrane-associated lymphocyte-specific protein tyrosine kinase (Lck) for initiation of signalin

185 he GRB2-GAB2 complex and lymphocyte-specific protein tyrosine kinase (LCK) in thymocytes.

186 The T lymphocyte-specific protein tyrosine kinase (Lck) is a key component of the

187 cisplatin resistance via lymphocyte-specific protein tyrosine kinase (LCK) signaling, which induced D

188 s) in the thymus through lymphocyte-specific protein tyrosine kinase (Lck) signaling.

189 , the close proximity of lymphocyte-specific protein tyrosine kinase (Lck) to the TCR induced by TCR-

190 reasing the frequency of lymphocyte-specific protein tyrosine kinase (Lck)-associated CD4 molecules i

191 protein arrays, the lymphocyte cell-specific protein-tyrosine kinase (LCK) as aberrantly activated in

192 e-based internalization motifs by Src family protein tyrosine kinases, leading to enhanced stable sur

193 ike nephritis in mice lacking the Src family protein tyrosine kinase Lyn (Lyn(-/-) mice).

194 aRIIB signaling, decreased expression of the protein tyrosine kinase Lyn, and increased serum levels

195 Protein-tyrosine kinase Lyn and Syk are critical for ant

196 signaling is dependent on the JAK family of protein tyrosine kinases, making JAK inhibition an appea

197 Although inhibitors of protein tyrosine kinases, MAPKs, and stress-activated ki

198 masK-815 indicate that MglA interacts with a protein tyrosine kinase, MasK, to control social motilit

199 cytosis, the myeloid-epithelial-reproductive protein tyrosine kinase (Mertk) and the milk fat globule

200 ly similar to those reported for Itk and Rlk protein tyrosine kinase mutants, including the increased

201 Nonreceptor protein tyrosine kinases (NRTKs) are essential for cellu

202 Protein tyrosine kinases of the JAK family have been sho

203 ryonic kidney (HEK) 293/TLR4/MD-2 cells with protein tyrosine kinase or Src kinase inhibitors suppres

204 nt work has demonstrated that the Src family protein tyrosine kinase p56Lck specifically links TCR si

205 merely terminating the pathways initiated by protein-tyrosine kinases, phosphatases are active partic

206 ic intracellular signaling pathways in which protein-tyrosine kinases, phosphatases, and adapter prot

207 mal signaling molecules (lymphocyte-specific protein tyrosine kinase, phospholipase Cgamma) were iden

208 ase in vitro, disrupting lymphocyte-specific protein tyrosine kinase phosphorylation and leading to i

209 ition for activation of cellular cascades of protein-tyrosine kinase phosphorylation following growth

210 The Syk protein-tyrosine kinase plays a major role in signaling

211 ErbB family of the receptor protein-tyrosine kinase plays an important role in the p

212 Because HK intake decreases Src family protein tyrosine kinase (PTK) activity an inhibitor of R

213 Protein tyrosine kinase (PTK) activity has been implicat

214 growth factor receptor (EGFR), the intrinsic protein tyrosine kinase (PTK) activity of one receptor m

215 discoidin (DS) domain (DeltaDS-DDR-2) or the protein tyrosine kinase (PTK) core (DeltaPTK-DDR-2), DDR

216 y potassium (K) intake stimulates Src family protein tyrosine kinase (PTK) expression via a superoxid

217 We performed a mutational analysis of the protein tyrosine kinase (PTK) gene family in cutaneous m

218 Cancer-associated protein tyrosine kinase (PTK) mutations usually are gain

219 kinase (Syk) phosphorylation and downstream protein tyrosine kinase (PTK) phosphorylation, Ca++ flux

220 unterparts play significant role in cellular protein tyrosine kinase (PTK) signaling pathways.

221 The first, ptk, encodes a putative protein tyrosine kinase (PTK), and the second, epsA, enc

222 in a mechanism that requires the Src family protein tyrosine kinase (PTK), Fyn.

223 (MEK), p38, c-Jun NH2-terminal kinase (JNK), protein tyrosine kinase (PTK), phosphatidylinositol 3-ki

224 tor and also not related to an inhibition of protein tyrosine kinase (PTK).

225 cer drug discovery that work in concert with protein tyrosine kinases (PTK) in controlling cellular h

226 motility during development in part through protein-tyrosine kinase (PTK) activation.

227 the development of skin cancer by promoting protein-tyrosine kinase (PTK) signaling.

228 suggest that AngII stimulates an Src family protein-tyrosine kinase (PTK) via PKC-NADPH oxidase.

229 role of CD63 in regulating ROMK1 channels by protein-tyrosine kinase (PTK).

230 Among these genes was the little studied protein tyrosine kinase PTK7.

231 uring biofilm formation to two proteins; the protein tyrosine kinase PtkA and the protein tyrosine ph

232 sphorylation of specific C-terminal sites by protein tyrosine kinases (PTKs) and C-type protein kinas

233 sine phosphorylation is tightly regulated by protein tyrosine kinases (PTKs) and protein tyrosine pho

234 It is regulated by the counter-activities of protein tyrosine kinases (PTKs) and protein tyrosine pho

235 ed by various cytokines, growth factors, and protein tyrosine kinases (PTKs) and regulates the transc

236 eversible oxidation, it is not clear whether protein tyrosine kinases (PTKs) are also directly regula

237 ded by activation of p38 MAPK, provided that protein tyrosine kinases (PTKs) are inhibited.

238 the distribution and activity of Src-family protein tyrosine kinases (PTKs) during zygotic developme

239 reduction in the level of active Src family protein tyrosine kinases (PTKs) in these eukaryotic cell

240 Protein tyrosine kinases (PTKs) play an important role i

241 binds more than a dozen proteins, including protein tyrosine kinases (PTKs), in a phosphorylation-de

242 2/3 complex, phosphatidylinositol-3'-kinase, protein tyrosine kinases (PTKs), Src family PTK, focal a

243 Regulated phosphorylation by protein tyrosine kinases (PTKs), such as c-Abl, is criti

244 ion, controlled by the coordinated action of protein-tyrosine kinases (PTKs) and protein-tyrosine pho

245 We now have identified the protein-tyrosine kinases (PTKs) and their substrates req

246 ss, we know much more about the functions of protein-tyrosine kinases (PTKs) than about protein-tyros

247 trates that the calcium-calmodulin sensitive protein tyrosine kinase PYK2 is a target of the fertiliz

248 The protein tyrosine kinase Pyk2 is highly expressed in oste

249 reduces phosphorylation and activity of the protein-tyrosine kinase Pyk2, an effect that may also co

250 Focal adhesion kinase (FAK)-related protein tyrosine kinase (Pyk2) is downstream of DDR1, wh

251 ntified interaction between Beclin-1 and the protein tyrosine kinase receptor Her2.

252 Here we show that transactivation of protein-tyrosine kinase receptors is mediated by matrix

253 affold signaling, and the transactivation of protein-tyrosine kinase receptors such as those for EGF

254 how that the functions of Src family and Abl protein tyrosine kinases require an electrostatic intera

255 ted factors (TRAF2 and TRAF6) and Src family protein tyrosine kinases (SF-PTKs) in a genetically and

256 s inhibition is attenuated by the Src-family protein tyrosine kinase (SFK).

257 of members of the Src family of nonreceptor protein tyrosine kinases (SFK) are commonly observed in

258 The Src family protein tyrosine kinases (SFKs) are crucial regulators o

259 ating from Lyn and Fyn, which are Src family protein tyrosine kinases (SFKs).

260 heral supramolecular activation cluster PTK: protein tyrosine kinase Signal transduction: biochemical

261 ion of transcription, transmembrane receptor protein tyrosine kinase signaling pathways, response to

262 TCPTP can function coordinately to regulate protein tyrosine kinase signaling, and PTP1B has been im

263 includes heterotrimeric G protein subunits, protein tyrosine kinases, small G proteins, Ca(2+), and

264 Here, we show that the protein tyrosine kinase Src arginine-388-->alanine (R388

265 Protein tyrosine kinase Src is a key enzyme in mammalian

266 The protein tyrosine kinase Src is involved in a multitude o

267 ocked by PP2, the selective inhibitor of the protein tyrosine kinase Src, which is known to be activa

268 Therefore, the activity of p60c-src protein tyrosine kinase (Src) on the developed tyrosine

269 f oxaliplatin sensitivity is the nonreceptor protein tyrosine kinase, Src, the activity of which corr

270 We showed previously that the adaptor protein tyrosine kinase substrate with five Src homology

271 Targeting more upstream protein tyrosine kinases such as spleen tyrosine kinase

272 ved in the early stages of TCR signaling are protein-tyrosine kinases such as Lck, Fyn, and ZAP-70.

273 We previously showed that protein-tyrosine kinases such as Src kinase and PTPs suc

274 as well as downstream phosphorylation of the protein tyrosine kinase Syk and activation of phospholip

275 ne phosphorylation, particularly that of the protein tyrosine kinase Syk and phospholipase C-gamma2,

276 In APCs, the protein tyrosine kinase Syk is required for signaling of

277 decrease in tyrosine phosphorylation of the protein tyrosine kinase Syk, as measured by absolute qua

278 , short-lived positive signals driven by the protein tyrosine kinase Syk; slow, long-lived negative s

279 The protein-tyrosine kinase Syk couples immune recognition r

280 The nonreceptor, protein-tyrosine kinase Syk is a suppressor of breast ca

281 e show that PKC-delta-mediated activation of protein-tyrosine kinase Syk plays an important role in t

282 n, the platelet FcgammaRIIa Fc receptor, the protein-tyrosine kinase Syk, and phospholipase Cgamma2.

283 es located close to the COOH terminus of the protein-tyrosine kinase Syk.

284 R, Lyn, Fyn, Csk, PAG1, and Syk, a cytosolic protein tyrosine kinase that is activated as a result of

285 ested whether a defect in LYN, an inhibitory protein tyrosine kinase that is implicated in systemic a

286 ZAP-70 is a cytoplasmic protein tyrosine kinase that is required for T cell anti

287 Csk and Src are two protein tyrosine kinases that share a similar overall mu

288 s identify ACK1 as a novel SLP-76-associated protein-tyrosine kinase that modulates early activation

289 GF-1R beta-subunit and BRK/PTK6, an SRC-like protein-tyrosine kinase that physically and functionally

290 Focal adhesion kinase (FAK) is a cytoplasmic protein-tyrosine kinase that promotes cell migration, su

291 s driven by Bcr-Abl, a constitutively active protein-tyrosine kinase that stimulates proliferation an

292 FAK) is a member of a family of non-receptor protein-tyrosine kinases that regulates integrin and gro

293 sidues alone may not be sufficient to enable protein tyrosine kinases to readily evolve novel binding

294 We have identified the receptor protein tyrosine kinase TYRO3 as an upstream regulator o

295 This assay is universally applicable to protein tyrosine kinases using a BV-tag-labeled monoclon

296 Pyk2 demonstrated that the activity of this protein tyrosine kinase was dispensable for the ability

297 ctivate as-yet-unidentified growth-promoting protein tyrosine kinases, which in turn contribute to th

298 ubstrates of spleen tyrosine kinase (Syk), a protein-tyrosine kinase with duel properties of an oncog

299 receptor (TCR) inside the cell relies on the protein tyrosine kinase ZAP-70 (zeta-associated protein

300 WAVE2 recruitment to the TCR site depends on protein-tyrosine kinase, ZAP-70, and the adaptors LAT, S